Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer
Menée sur 399 femmes présentant des saignements utérins anormaux (âge : 45 ans et plus), cette étude évalue, par rapport à une échographie, la performance d'un test, basé sur la méthylation des régions génomiques ZSCAN12 et GYPC, pour détecter un cancer de l'utérus
Endometrial cancer is the most common gynaecological cancer in high-income countries, with an increasing incidence worldwide. Survival is highly correlated with stage, making early detection and treatment essential. Although the number of cancers diagnosed among younger women is increasing, most endometrial cancers are still detected in perimenopausal or postmenopausal patients at an early stage when they present with abnormal uterine bleeding. Clinical evaluation includes pelvic examination, imaging, and endometrial biopsy. Pelvic ultrasound is the most used imaging test but has limited sensitivity and specificity for endometrial cancer. The gold standard for diagnosis remains endometrial sampling. Both tests require specialist referrals and the use of painful and anxiety-provoking procedures. Patient and physician groups have begun advocating for methods that can expedite appropriate diagnosis and referral with less invasive approaches.
The Lancet Oncology , commentaire, 2022